Elutia Inc
NASDAQ:ELUT

Watchlist Manager
Elutia Inc Logo
Elutia Inc
NASDAQ:ELUT
Watchlist
Price: 4.38 USD -9.5% Market Closed
Market Cap: 151.4m USD
Have any thoughts about
Elutia Inc?
Write Note

Elutia Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Elutia Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Elutia Inc
NASDAQ:ELUT
Current Portion of Long-Term Debt
$3.3m
CAGR 3-Years
-19%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Current Portion of Long-Term Debt
$12.6B
CAGR 3-Years
24%
CAGR 5-Years
19%
CAGR 10-Years
89%
Gilead Sciences Inc
NASDAQ:GILD
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Current Portion of Long-Term Debt
$3.5B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Elutia Inc
Glance View

Market Cap
151.4m USD
Industry
Biotechnology

Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.

ELUT Intrinsic Value
6.79 USD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is Elutia Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
3.3m USD

Based on the financial report for Dec 31, 2023, Elutia Inc's Current Portion of Long-Term Debt amounts to 3.3m USD.

What is Elutia Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
2%

The average annual Current Portion of Long-Term Debt growth rates for Elutia Inc have been -19% over the past three years , 2% over the past five years .

Back to Top